Patients and tumour characteristics, concomitant diseases
| All N = 175 (100%) | Left BC group N = 84 (48%) | Right BC group N = 91 (52%) | p value | ||
|---|---|---|---|---|---|
| Age in years (Median [Q1–Q3]) | 58 (49–64) | 59 (52–67) | 55 (46–63) | 0.0096 | |
| Menopause status | Premenopause | 90 (51.4%) | 38 (45.2%) | 52 (57.1%) | 0.155 |
| Pomenopause | 85 (48.5%) | 46 (54.8%) | 39 (42.9%) | ||
| Histological type | Ductal invasive | 168 (96%) | 81 (96.4%) | 87 (95.6%) | 1 |
| Lobular invasive | 4 (2.3%) | 2 (2.4%) | 2 (2.2%) | ||
| Other | 3 (1.7%) | 1 (1.2%) | 2 (2.2%) | ||
| Histo-pathological grade | G 1 | 2 (1.1%) | 0 | 2 (2.2%) | 0.337 |
| G 2 | 48 (27.4%) | 21 (25%) | 27 (29.7%) | ||
| G 3 | 125 (71.5%) | 63 (75%) | 62 (68.1%) | ||
| Hormonal receptors | ER positive | 97 (55.4%) | 53 (63%) | 44 (48.3%) | 0.851 |
| PR positive | 82 (46.8%) | 43 (51.2%) | 39 (42.8%) | ||
| ER in PR negative | 73 (41.7%) | 28 (33.3%) | 45 (49.4%) | ||
| Concomitant disease | Smoking | 33 (19%) | 13 (15%) | 20 (22%) | 0.365 |
| Arterial hypertension | 35 (20%) | 21 (25%) | 14 (15.4%) | 0.161 | |
| Diabetes | 3 (1.7%) | 3 (3.4%) | 0 | 0.108 | |
| Hyperlipidemia | 30 (17.1%) | 16 (19%) | 14 (15.4%) | 0,658 | |
| Known heart disease All diseases had been already present at diagnosis of breast cancer. Group 1: mild aortic stenosis; Group 2: mitral valve prolapse; compensated hypertonic heart and symptomatic angina pectoris; undefined cardiomyopathy | 4 (2.3%) | 1 (1.2%) | 3 (3.3%) | 0.621 |
Systemic treatment and surgical characteristics
| All (N = 175) (%) | Left BC Group (N = 84) (%) | Right BC Group (N = 91) (%) | P value | |
|---|---|---|---|---|
| Anthracyclines | ||||
| Cumulative dose- mg/m2 BSA | ||||
| (Median [Q1–Q3]) | 350 (292–499) | 352 (295–497) | 349 (290–499) | 0.799 |
| Taxanes | ||||
| Cumulative dose- mg/m2 BSA | 297 | 297 | 298 | 0.783 |
| (Median [Q1–Q3]) | (276–594) | (281–422) | (273–768) | |
| Cyclophosphamide | ||||
| Cumulative dose- mg/m2 BSA | 2316 | 2344 | 2268 | 0.482 |
| (Median [Q1–Q3]) | (1758–2924) | (1763–2992) | (1758–2829) | |
| CT Scheme | ||||
| AC/EC/FAC/FEC + taxanes | 95 (54.3%) | 40 (47.6%) | 55 (60.4%) | 0.235 |
| AC/EC/FAC/FEC without taxanes | 69 (39.4%) | 38 (45.3%) | 31 (34.1%) | |
| Other | 11 (6.3%) | 6 (7.1%) | 5 (5.5%) | |
| Endocrine therapy | ||||
| Tamoxifen | 39 (22.3%) | 21 (25%) | 18 (19.8%) | 0.652 |
| Aromatase inhibitor | 45 (25.7%) | 26 (30.9%) | 19 (20.8%) | |
| Other | 10 (5.7%) | 7 (8.3%) | 3 (3.3%) | |
| Trastuzumab | ||||
| Cumulative dose- mg/kg BSA | 105 (97–114) | 105 (97–116) | 105 (97–112) | 0.658 |
| (Median [Q1–Q3]) | ||||
| Type of surgery | ||||
| Mastectomy | 91 (52%) | 38 (45.2%) | 53 (58.2%) | 0.116 |
| Breast conserving surgery | 84 (48%) | 46 (54.8) | 38 (41.8%) |
Analysis of the difference in left ventricular ejection fractions (Δ LVEF)
| All (N = 175) | Left BC Group (N = 84) | Right BC Group (N = 91) | P value | |
|---|---|---|---|---|
| LVEF0 (%) | 65 (60–69) | 65 (61–70) | 63 (59.5–67) | 0.0208 |
| (Median [Q1–Q3]) | ||||
| LVEF1 (%) | 66 (62–70) | 67 (64–70) | 65 (60–70.5) | 0.117 |
| (Median [Q1–Q3]) | ||||
| Analysis of Δ LVEF | (n = 149) | (n = 70) | (n = 79) | 0.562 |
| LVEF0 (%)-LVEF1(%) = Δ LVEF | -2.22 (8.69) | -1.78 (7.85) | -2.60 (9.4) | 95% CI: -2.004 – 3.648 |
| (Mean [SD]) |
Echocardiografic parameters (n = 175)
| Left BC Group (n = 84) (median [Q1–Q3]) | Right BC Group (n = 91) (median [Q1–Q3]) | p value | |
|---|---|---|---|
| LV EDD (cm) | 4.6 (4.4–4.9) | 4.6 (4.4–4.8) | 0.913 |
| 95% CI (-0.10-0.10) | |||
| LV ESD (cm) | 2.9 (2.6–3.1) | 2.8 (2.5–3.2) | 0.541 |
| 95% CI (-0.19–0.10) | |||
| LA tr (cm) | 3.4 (3.2–3.8) | 3.4 (3.2–3.7) | 0.830 |
| 95% CI (-0.10–0.10) | |||
| LA long (cm) | 4.4 (4.0–4.8) | 4.5 (4.2–4.6) | 0.979 |
| 95% CI (-0.10–0.10) | |||
| RA tr (cm) | 3.2 (3.0–3.6) | 3.4 (3.0–3.7) | 0.298 |
| 95% CI (-0.20–0.00) | |||
| RA long (cm) | 4.1 (3.8–4.4) | 4.3 (3.9–4.4) | 0.226 |
| 95% CI (-2.0–3.00) | |||
| LVEF (%) | 68.5 (64–74.2) | 68.0 (63.0–72.5) | 0.758 |
| 95% CI (-2.0–3.00) | |||
| E/A | 1.07 (0.80–1.23) | 1.08 (0.87–1.32) | 0.113 |
| 95% CI (-0.18–0.02) | |||
| E/Em | 7.15 (6.27–9.26) | 7.40 (6.18–8.68) | 0.918 |
| 95% CI (-0.52–0.66) | |||
| s/d | 1.368 (1.065–1.600) | 1.149 (0.94–1.35) | 0.002 |
| 95% CI ( 0.07–0.29) | |||
| TDI Sm (cm/s) | 8.0 (7.0–9.1) | 8.0 (7.0–9.1) | 0.985 |
| 95% CI (-0.50–0.50) | |||
| TDI Em (cm/s) | 10.0 (7.82–11.37) | 10.0 (8.05–11.8) | 0.547 |
| 95% CI (-0.10–0.50) |
Radiotherapy treatment features
| All (N = 175) (%) | Left BC group (N = 84) (%) | Right BC group (N = 91) (%) | p value | |
|---|---|---|---|---|
| RT field parasternal lymph nodes were not included in the irradiated area | ||||
| Breast | 70 (40%) | 38 (45.3%) | 32 (35.2%) | 0.434 |
| Breast + scl | 17 (9.7%) | 9 (10.7%) | 8 (8.8%) | |
| Thoracic wall | 17 (9.7%) | 8 (9.5%) | 9 (9.9%) | |
| Thoracic wall + scl | 71 (40.6%) | 29 (34.5%) | 42 (46.1%) | |
| RT technique | ||||
| 2D RT | 139 (79.4%) | 69 (82.1%) | 70 (76.9%) | 0.256 |
| 3D CRT | 25 (14.3%) | 12 (14.3%) | 13 (14.3%) | |
| Electrons +/- photons | 11 (6.3%) | 3 (3.6%) | 8 (8.8%) | |
| RT scheme | ||||
| 25 × 2 Gy | 14 (84.6%) | 73 (86.9%) | 75 (82.4%) | 0.540 |
| 17 or 18 × 2.5 Gy | 27 (15.4%) | 11 (13.1%) | 16 (17.6%) |
Pericardial effusion
| ECHO | All (N = 174) (%) | Left BC Group (N = 83) (%) | Right BC Group (N = 91) (%) | p value | |
|---|---|---|---|---|---|
| Pericard | Normal | 164 (94.3%) | 74 (89%) | 90 (99%) | 0.007 |
| Effusion | 10 (5.7%) | 9 (11%) | 1 (1%) |